Brink Biologics

San Diego, US · 1 known investors

Brink Biologics provides NK-92 cell lines and assay panels for antibody-dependent cell-mediated cytotoxicity (ADCC) testing in therapeutic antibody development. The company offers proprietary Neukopanel cell lines and related services to pharmaceutical and biotechnology companies developing cancer and immunotherapy treatments.